Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
357
Enrollment
INDUSTRY
Sponsor class

Stopped SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed.

Conditions

Interventions

Sponsor

Biogen